Wednesday, June 11, 2014

Conatus Pharma Breaks From Intercept's Shadow?

Bloggers and traders alike are scratching their heads, looking for answers as to why Conatus Pharmaceuticals (CNAT) is up more than 48% intraday today.

Short of any company comments and my own hubris, Premium subscribers over at PropThink.com profitably know why: "Intercept  Isn't the Only Way to Play Liver Disease."

To wit: [excerpt] "Similarly focused on liver disease treatments, Conatus Pharmaceuticals (CNAT) has risen and fallen on parallel developments for Intercept Pharmaceuticals’ (ICPT) obeticholic acid (OCA). A series of favorable emricasan updates in the next 12 months, including Phase 2 updates in patients with nonalcoholic fatty liver disease (NAFLD) or fibrotic nonalcoholic steatohepatitis (NASH), could allow investors to better assess the commercial opportunities of CNAT’s lead compound – and finally free the stock price from Intercept’s shadow."

Editor David J Phillips does not hold a financial interest in any stocks mentioned in this article. The 10Q Detective has a Full Disclosure Policy.